Letter to the Editor

Rates of Inhibitor Development in Previously Untreated Patients with Severe Hemophilia A Treated with Plasma-Derived or Recombinant Factor VIII: No Proof of Difference or Proof of No Difference?

Andrea Messori, PharmD¹ Valeria Fadda, PharmD¹ Dario Maratea, PharmD¹ Sabrina Trippoli, PharmD¹

¹ HTA Unit, ESTAV Toscana Centro, Regional Health Service, Firenze, Italy

Semin Thromb Hemost 2014;40:269–270.

Address for correspondence Andrea Messori, PharmD, ESTAV Centro, Area Vasta Centro Toscana, Regional Health System, Via Guimaraes 9-11, 59100 Prato, Italy (e-mail: andrea.messori.it@gmail.com; andrea.messori@estav-centro.toscana.it).

The issue of comparing the rates of inhibitor development in previously untreated patients with severe hemophilia A who are treated with plasma-derived Factor VIII concentrates (pdFVIII) or recombinant Factor VIII (rFVIII) is influenced by numerous and unavoidable biases. These biases essentially depend on the observational nature of the data and on the recognition that factors other than the type of product might be implicated. In this framework, the meta-analysis by Franchini et al¹ represents the most comprehensive and updated attempt to shed light on this controversial topic.

In the discussion of the results of this meta-analysis, one key of interpretation has not been considered by the authors but deserves, in our view, to be pointed out. The question essentially is: Do these results represent no proof of difference or proof of no difference?

When a traditional meta-analysis generates a nonsignificant result, the need to differentiate between no proof of difference or proof of no difference is increasingly being recognized^{2–5}; in fact, in the first case the results should be viewed as inconclusive (i.e., no demonstration of anything) while in the second case a statistical proof is obtained that no difference exists (i.e., demonstration of equivalence or noninferiority).

To address this specific question, we have reanalyzed the results described by Franchini et al by carrying out a formal equivalence test based on 95% confidence intervals (CIs). The objective was to compare the inhibitor development rates between pdFVIII and rFVIII; the main assumption of our analysis was that the margins for equivalence are set at $0 \pm 4.0\%$.

—**Fig. 1** summarizes our reanalysis. To determine the 95% CIs shown in ►**Fig. 1**, we first repeated the proportion meta-analysis of Franchini et al and we exactly confirmed the meta-analytic results published by the Italian authors (details on

our repeated meta-analysis with study-specific crude rates and Forest plots can be seen from our institutional Web site at <http://www.sifact.it/firenze/sth-messori-supplement.pdf>;

Fig. 1 Rates of inhibitor development in previously untreated patients with severe hemophilia A: test of equivalence applied to recombinant Factor VIII in comparison with plasma-derived Factor VIII. The graph is based on the same primary data as those reported by Franchini et al¹ in their Table 2. The absolute risk was 23% (95% confidence interval [CI], 15–33%) in patients treated with plasma-derived concentrates and 29% (95% CI, 26–32%) in those treated with recombinant Factor VIII. The equivalence test is based on the area comprised between the two red vertical lines, that reflect the predetermined equivalence margins (around the value of rate difference = $0 \pm 4.0\%$). The horizontal black line indicates the two-sided 95% CI (or one-sided 97.5% CI) for the pooled value of rate difference between rFVIII and pdFVIII found by Franchini et al (point estimate represented by the solid square); the estimation of this 95% CI, which is the crucial step in equivalence testing, was performed according to the methods described by Ahn et al⁶ and Hausleiter et al.⁷ Accordingly, the standard error for the pooled rate difference was first estimated (standard error = 5.335%) and then the lower and upper extremes for this 95% CI were determined (–4.46 and +16.46%, respectively).

published online
February 5, 2014

Issue Theme Quality in Hemostasis and Thrombosis, Part III; Guest Editors, Emmanuel J. Favaloro, PhD, FFSc (RCPA), Giuseppe Lippi, MD, and Mario Plebani, MD.

Copyright © 2014 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA.
Tel: +1(212) 584-4662.

DOI <http://dx.doi.org/10.1055/s-0034-1367471>.
ISSN 0094-6176.

confirmation of the crude rates was a prerequisite for undertaking our equivalence analysis. The main result of our equivalence analysis was that the pooled rate difference of +6% for rFVIII versus pdFVIII (i.e., the difference between the two point estimates of 29 vs. 23%, respectively) is associated to a standard error of 5.335% and to a 95% CI ranging from -4.46 to +16.46%. According to our reanalysis, the published data reported by the Italian authors clearly represent no proof of difference.

More importantly, our results show that these data do not support the conclusion of proof of no difference (i.e., equivalence) unless one extends the definition of equivalence up to an unrealistic margin of $0 \pm 17.0\%$. Another unsettled question is that the need to differentiate between different products containing rFVIII further increases the difficulty in studying this topic.

We conclude that, despite the inclusion of the best evidence currently available, we still do not know whether or not rFVIII is associated to an increased rate of inhibitor development as compared with pdFVIII. Finally, while we admit that most of the considerations presented herein were implicit in the article by Franchini et al, we think that making these points more explicit is worthwhile.

Acknowledgment

The authors have performed this study in the context of their activity at the above mentioned institution; ESTAV Centro belongs to the Italian national health system.

Conflict of Interests

None declared.

References

- 1 Franchini M, Coppola A, Rocino A, et al; Italian Association of Hemophilia Centers (AICE) Working Group. Systematic review of the role of FVIII concentrates in inhibitor development in previously untreated patients with severe hemophilia a: a 2013 update. *Semin Thromb Hemost* 2013;39(7):752–766
- 2 Arruda MA. No evidence of efficacy or evidence of no efficacy. *JAMA Pediatr* 2013;167(3):300–302
- 3 Messori A, Fadda V, Maratea D, Trippoli S. Erythropoietin in patients with acute myocardial infarction: no proof of effectiveness or proof of no effectiveness? *Clin Cardiol* 2013;36(10):E39–E40
- 4 Messori A, Fadda V, Maratea D, Trippoli S. Erythropoiesis-stimulating agents in heart failure: no proof of effectiveness or proof of no effectiveness? *Eur J Heart Fail* 2013;15(8):944–945
- 5 Messori A, Fadda V, Maratea D, Trippoli S. ω -3 fatty acid supplements for secondary prevention of cardiovascular disease: from “no proof of effectiveness” to “proof of no effectiveness”. *JAMA Intern Med* 2013;173(15):1466–1468
- 6 Ahn S, Park SH, Lee KH. How to demonstrate similarity by using noninferiority and equivalence statistical testing in radiology research. *Radiology* 2013;267(2):328–338
- 7 Hausleiter J, Meyer TS, Martuscelli E, et al. Image quality and radiation exposure with prospectively ECG-triggered axial scanning for coronary CT angiography: the multicenter, multivendor, randomized PROTECTION-III study. *JACC Cardiovasc Imaging* 2012;5(5):484–493